ArticleExperimental biology and medicine (Maywood, N.J.)2023
Cassava microfiber-reinforced gelatin scaffold holds promise for tissue engineering by exhibiting cytocompatibility with HEK 293 cells.
Article in Experimental biology and medicine (Maywood, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Phytochemical, Nutritional and Medicinal Properties of Manihot esculenta Leaves: An Integrated Review of Nutritional and Anticancer Insights.Plant foods for human nutrition (Dordrecht, Netherlands) · 2026Review
- Fabrication of Bilayer Nanofibrous-Hydrogel Scaffold fromACS omega · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellulose fiber-reinforced composite scaffolds have recently become an interesting target for biomedical and tissue engineering (TE) applications. Cassava bagasse, a fibrous solid residue obtained after the extraction of cassava starch and soluble sugars, has been explored as a potential source of cellulose and has been successfully used to enhance the mechanical properties of gelatin scaffolds for TE purposes. This study assessed the cytocompatibility of the cassava microfiber-gelatin composite scaffold using human embryonic kidney cells (HEK 293) and a breast cancer cell line (MDA MB 231) under ISO 10993-5 standards. The viability of cells within the composite scaffold was analyzed through MTT assay. The growth of HEK 293, as well as the cell morphology, was not affected by the presence of cellulose within the composite, whereas the growth of breast cancer cells appeared to be inhibited with noticeable changes in cell morphology. These findings suggest that the presence of the cassava fiber in gelatin is not cytotoxic to HEK 293 cells. Thus, the composite is suitable for TE purposes when using normal cells. On the contrary, the presence of the fiber in gelatin elicited a cytotoxic effect in MDA MB 231 cells. Thus, the composite may not be considered for three-dimensional (3D) tumor cell studies requiring cancer cell growth. However, further studies are required to explore the use of the fiber from cassava bagasse for its anticancer cell properties, as observed in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.